RxDoctor Payments DataLook up a doctor →

Jai Radhakrishnan, MD

Nephrology · New York, NYNPI 1275605446

Payments from drug & device makers

$995,057in general payments, 2019–2025

Across 393 payments — averaging $2531.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$355K
  • Bayer$106K
  • Boston Scientific$103K
  • Amgen$75K
  • Vertex$70K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$58K
  • plus $228K from 23 others
$32,722in research payments, 2019–2025

Across 5 payments — averaging $6544.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$28K
  • Novartis Pharma AG$5K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$995,057 in reported general payments places this provider in the 95th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$160,130
Medicare patients
293
Services billed
1,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nephrology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →